EUSA Pharma buys renal cell carcinoma rights to tivozanib for Europe, South America and South Africa- Aveo Oncology

AVEO Oncology and EUSA Pharma announced an exclusive license agreement in which AVEO has granted EUSA Pharma European rights to tivozanib for the treatment of advanced renal cell carcinoma (RCC). The agreement also includes a number of additional territories outside North America, including South America and South Africa, and additional potential indications. EUSA Pharma plans to submit a Marketing Authorization Application for tivozanib as a first line treatment for advanced RCC to the European Medicines Agency in the first quarter of 2016.

Comment: After the FDA rejected tivozanib in 2013, the agency told AVEO that it may reconsider the drug as a third-line treatment for advanced RCC based on a newly proposed clinical trial design.